Bringing you live news and features since 2006 

Biotech and pharma ETF launch from iShares


iShares has launch a new ETF offering access to biotechnology and pharmaceutical companies from the US. The ETF is traded on Xetra and Börse Frankfurt.

The firm writes that the iShares NASDAQ US Biotechnology UCITS ETF enables investors to participate in the performance of biotechnology and pharmaceutical companies from the US. The index components must be listed on NASDAQ and meet set admission criteria on market capitalisation and liquidity. The maximum weighting of an index component is eight percent. In addition, a maximum of five index components are permitted to reach this limit.

Latest News

Saving and investing app, Moneybox, has doubled the number of ETFs available on the platform, in the light of ‘growing..
Global X ETFs has announced the appointment of Ryan O'Connor as its Chief Executive Officer effective as of April 8, 2024. ..
Value-driven structured credit investing firm, Angel Oak Capital Advisors, LLC, has announced the completed conversions of two of its mutual..
Confidence in the continuing strength of bitcoin and Ethereum is driving wider interest in altcoins and other digital assets, according..

Related Articles

Graham MacKenzie, Toronto Stock Exchange
The evolution of ETFs has been a multi-decade experience for Toronto Stock Exchange says Graham MacKenzie, managing director, Exchange Traded...
Frank Koudelka, State Street Global Services
ETF data provider and ETF Express data partner, Trackinsight, has published its Global ETF Survey 2024 Report: ‘50+ Charts on...
Matteo Greco, Research Analyst at Fineqia International writes that bitcoin (BTC) ended the week at approximately USD52,150, showing a notable...
US Distribution Awards trophies
The winners of the first US ETF Distribution Awards at the Exchange conference, hosted by ETF Express and sponsored by...
Subscribe to the ETF Express newsletter

Subscribe for access to our weekly newsletter, newsletter archive, updates on the site and exclusive email content.

Marketing by